Pathophysiological implication of the structural domains of lipoprotein(a)

Atherosclerosis

Volumn 133, Issue 1, 1997, Pages 1-6

  Huby, Thierry ^a   Chapman, John ^a   Thillet, Joëlle ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Apolipoprotein(a); Catabolism; Kringles; Lipoprotein(a); Structural domains

Indexed keywords

APOLIPOPROTEIN; LIPOPROTEIN A;

AMINO TERMINAL SEQUENCE; ATHEROSCLEROSIS; CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR DISEASE; CATABOLISM; LIPOLYSIS; LIPOPROTEIN BLOOD LEVEL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0030797815     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(97)00111-1     Document Type: Article

References (48)

1. Berg K. A new serum type system in man: the Lp-system.. Acta Pathol Microbiol Scand 1963;59:369-82.
2. Maher VMG, Brown BG. Lipoprotein(a) and coronary heart disease. Curr Opin Lipidol 1995;6:229-35.
3. Pepin JM, O'Neil JA, Hoff HF. Quantification of apo(a) and apoB in human atherosclerotic lesions. J Lipid Res 1991;32:317-27.
4. Smith EB, Cochran S. Factors influencing the accumulation in fibrous plaques of lipid derived from low density lipoprotein. II. Preferential immobilization of lipoprotein(a) (Lp(a)). Atherosclerosis 1990;84:173-81.
5. Loscalzo J, Weinfield M, Fless GM, Scanu AM. Lipoprotein(a), fibrin binding and plasminogen activation. Arterioscler Thromb 1990;10:240-5.
6. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with apolipoprotein(a). Nature 1989;339:301-3.
7. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989;339:303-5.
8. Rouy D, Grailhe P, Nigon F, Chapman J, Angles-Cano E. Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator. Arterioscler. Thromb. 1991;11:629-38.
9. Williams JK, Bellinger DA, Nichols TC, et al. Occlusive arterial thrombosis in cynomolgus monkeys with varying plasma concentrations of lipoprotein(a). Arterioscler Thromb 1993;13:548-54.
10. Palabrica TM, Liu AC, Aronovitz MJ, Furie B, Lawn RM, Furie BC. Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nat Med 1995;1:256-9.
11. Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science 1993;260:1655-8.
12. Callow MJ, Rubin EM. Site-specific mutagenesis demonstrates that cysteine 4326 of apolipoprotein B is required for covalent linkage with apolipoprotein(a) in vivo. J Biol Chem 1995;270:23914-7.
13. Koschinsky ML, Cote GP, Gabel B, Vanderhoek YY. Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein-B-100. J Biol Chem 1993;268:19819-25.
14. McLean JW, Tomlinson JE, Kuang WJ, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987;330:132-7.
15. Guevara J, Knapp RD, Honda S, Northup SR, Morrisett JD. A structural assessment of the apo(a) protein of human lipoprotein(a). Proteins Struct Funct Genet 1992;12:188-99.
16. Vanderhoek YY, Wittekoek ME, Beisiegel U, Kastelein JJP, Koschinsky ML. The apolipoprotein(a) kringle-IV repeats which differ from the major repeat kringle are present in variably-sized isoforms. Hum Mol Genet 1993;2:361-6.
17. Henkin J, Marcotte P, Yang H. The plasminogen-plasmin system. Prog Cardovasc Dis 1991;34:135-64.
18. Nakumara T, Nishizawa T, Hagiya M, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989;342:440-3.
19. Yoshimura T, Yuhki N, Wang MH, Skeel A, Leonard EJ. Cloning, sequencing, and expression of human macrophage stimulating protein (MSP, MST1) confirms MSP as a member of the family of kringle proteins and locates the MSP gene on chromosome-3. J Biol Chem 1993;268:15461-8.
20. Choimiura NH, Tobe T, Sumiya J, et al. Purification and characterization of a novel hyaluronan-binding protein (PHBP) from human plasma: it has three EGF, a kringle and a serine protease domain, similar to hepatocyte growth factor activator. J Biochem Tokyo 1996;119:1157-65.
21. de Vos AM, Ultsch MH, Kelley RF, et al. Crystal structure of the kringle 2 domain of tissue plasminogen activator at 2.4 A resolution. Biochemistry 1992;31:270-9.
22. Mulichak AM, Tulinsky A, Ravichandran KG. Crystal and molecular structure of human plasminogen kringle 4 refined at 1.9 Åresolution. Biochemistry 1991;30:10576-88.
23. Gaubatz JW, Heideman C, Gotto AM, Morrisett JD, Dahlen GH. Human plasma lipoprotein (a). Structural properties. J Biol Chem 1983;258:4582-9.
24. Fless GM, ZumMallen ME, Scanu AM. Physicochemical properties of apolipoprotein(a) and lipoprotein(a-) derived from the dissociation of human plasma lipoprotein(a). J Biol Chem 1986;261:8712-8.
25. Phillips ML, Lembertas AV, Schumaker VN, Lawn RM, Shire SJ, Zioncheck TF. Physical properties of recombinant apolipoprotein(a) and its association with LDL to form an Lp(a)-like complex. Biochemistry 1993;32:3722-8.
26. Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 1987;80:458-65.
27. Lackner C, Cohen JC, Hobbs HH. Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Mol Genet 1993;2:933-40.
28. Marcovina SM, Hobbs HH, Albers JJ. Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel: Basis for a standardized isoform nomenclature. Clin Chem 1996;42:436-9.
29. Sandholzer C, Saha N, Kark JD, et al. Apo(a) isoforms predict risk for coronary heart disease. A study in six populations. Arterioscler Thromb 1992;12:1214-26.
30. Kraft HG, Lingenhel A, Bader G, Kostner GM, Utermann G. The relative electrophoretic mobility of apo(a) isoforms depends on the gel system: proposal of a nomenclature for apo(a) phenotypes. Atherosclerosis 1996;125:53-61.
31. Farrer M, Game FL, Albers CJ, et al. Coronary artery disease is associated with increased lipoprotein(a) concentrations independently of the size of circulating apolipoprotein(a) isoforms.. Arteriosler Thromb 1994;14:1272-83.
32. Hervio L, Chapman MJ, Thillet J, Loyau S, Anglescano E. Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis. Blood 1993;82:392-7.
33. Leerink CB, Duif PFCCM, Verhoeven N, et al. Apolipoprotein(a) isoform size influences binding of lipoprotein(a) to plasmin-modified des-AA-fibrinogen. Fibrinolysis 1994;8:214-20.
34. Gries A, Fievet C, Marcovina S, et al. Interaction of LDL, Lp(a) and reduced Lp(a) with monoclonal antibodies against apoB. J Lipid Res 1988;29:18.
35. Zawadzki Z, Tercé F, Seman LJ, et al. The linkage with apolipoprotein (a) in lipoprotein (a) modifies the immunochemical and functional properties of apolipoprotein B. Biochemistry 1988;27:8474-81.
36. Huby T, Doucet C, Dieplinger H, Chapman J, Thillet J. Structural domains of apolipoprotein(a) and its interaction with apolipoprotein B-100 in the lipoprotein(a) particle. Biochemistry 1994;33:3335-41.
37. Edelstein C, Italia JA, Klezovitch O, Scanu AM. Functional and metabolic differences between elastase-generated fragments of human lipoprotein[a] and apolipoprotein[a]. J Lipid Res 1996;37:1786-801.
38. Harpel PC, Gordon BR, Parker TS. Plasmin catalyses binding of lipoprotein(a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci 1989;86:3847-51.
39. Rouy D, Grailhe P, Nigon F, Chapman J, Angles-Cano E. Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator. Arterioscler Thromb 1991;11:629-38.
40. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989;339:303-5.
41. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with apolipoprotein(a). Nature 1989;339:301-3.
42. Edelberg JM, Gonzalez-Gronow M, Pizzo SV. Lipoprotein(a) inhibition of plasminogen activation by tissue-type plasminogen activator.. Thrombosis Res 1990;57:155-62.
43. Edelberg JM, Gonzalez-Gronow M, Pizzo SV. Lipoprotein(a) inhibits streptokinase-mediated activation of human plasminogen. Biochemistry 1989;28:2370-4.
44. Huby T, Schroder W, Doucet C, Chapman J, Thillet J. Characterization of the N-terminal and C-terminal domains of human apolipoprotein(a): relevance to fibrin binding. Biochemistry 1995;34:7385-93.
45. Oida K, Takai H, Maeda H, et al. Apolipoprotein(a) is present in urine and its excretion is decreased in patients with renal failure.. Clin Chem 1992;38:2244-8.
46. Mooser V, Seabra MC, Abedin M, Landschulz K, Marcovina S, Hobbs HH. Apolipoprotein(a) kringle 4-containing fragments in human urine - relationship to plasma levels of lipoprotein(a). J Clin Invest 1996;97:858-64.
47. Kostner KM, Maurer G, Huber K, et al. Urinary excretion of Apo(a) fragments - role in Apo(a) catabolism. Arterioscler Thromb Vasc Biol 1996;16:905-11.
48. Hoff HF, Oneil J, Smejkal GB, Yashiro A. Immunochemically detectable lipid-free apo(a) in plasma and in human atherosclerotic lesions. Chem Phys Lipids 1994;67(8):271-80.